Document is current
Any future updates will be listed below
-
Authors
Orchard, Trevor J.
Cariou, Bertrand
Connelly, Margery A.
Otvos, James D.
Zhang, Shuyu
Antalis, Caryl J.
Ivanyi, Tibor
Hoogwerf, Byron J.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01481779 at ClinicalTrials.govnct01435616 at ClinicalTrials.govDocuments that mention this clinical trial
Cytokeratin-18 and Enhanced Liver Fibrosis Scores in Type 1 and Type 2 Diabetes and Effects of Two Different Insulins
https://doi.org/10.1136/jim-2017-000609
The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes
https://doi.org/10.1186/s12933-017-0555-1
Accurate Collection of Reasons for Treatment Discontinuation to Better Define Estimands in Clinical Trials
https://doi.org/10.1007/s43441-022-00491-0
nct01454284 at ClinicalTrials.govDocuments that mention this clinical trial
Cytokeratin-18 and Enhanced Liver Fibrosis Scores in Type 1 and Type 2 Diabetes and Effects of Two Different Insulins
https://doi.org/10.1136/jim-2017-000609
Accurate Collection of Reasons for Treatment Discontinuation to Better Define Estimands in Clinical Trials
https://doi.org/10.1007/s43441-022-00491-0
The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes
https://doi.org/10.1186/s12933-017-0555-1
nct01582451 at ClinicalTrials.govDocuments that mention this clinical trial
Cytokeratin-18 and Enhanced Liver Fibrosis Scores in Type 1 and Type 2 Diabetes and Effects of Two Different Insulins
https://doi.org/10.1136/jim-2017-000609
Accurate Collection of Reasons for Treatment Discontinuation to Better Define Estimands in Clinical Trials
https://doi.org/10.1007/s43441-022-00491-0
The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes
https://doi.org/10.1186/s12933-017-0555-1
Documents that mention this clinical trial
Cytokeratin-18 and Enhanced Liver Fibrosis Scores in Type 1 and Type 2 Diabetes and Effects of Two Different Insulins
https://doi.org/10.1136/jim-2017-000609
The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes
https://doi.org/10.1186/s12933-017-0555-1
Accurate Collection of Reasons for Treatment Discontinuation to Better Define Estimands in Clinical Trials
https://doi.org/10.1007/s43441-022-00491-0
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 6 March 2017
Accepted: 26 May 2017
First Online: 6 June 2017
